Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

被引:106
|
作者
Preaud, Emmanuelle [1 ]
Durand, Laure [2 ]
Macabeo, Berengere [2 ]
Farkas, Norbert [3 ]
Sloesen, Brigitte [4 ]
Palache, Abraham [5 ]
Shupo, Francis [6 ]
Samson, Sandrine I. [1 ]
机构
[1] Sanofi Pasteur MSD, F-69367 Lyon, France
[2] Sanofi Pasteur, F-69007 Lyon, France
[3] Novartis Vaccines & Diagnost AG, CH-4056 Basel, Switzerland
[4] GlaxoSmithKline, Rixensart, Belgium
[5] Abbott, NL-1381 CP Weesp, Netherlands
[6] Creativ Ceut Ltd, London SE1 9QQ, England
关键词
Influenza; Public health policy; Vaccines and immunization; Modeling; Epidemiology; COST-EFFECTIVENESS; EXCESS MORTALITY; ENGLAND; BURDEN; NORWAY; IMPACT; UNION;
D O I
10.1186/1471-2458-14-813
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels. Methods: A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data. Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza-related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional +(sic)190 to +(sic)226 million yearly, in vaccination target groups. Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Annual public health and economic benefits of seasonal influenza vaccination: a European estimate
    Emmanuelle Preaud
    Laure Durand
    Bérengère Macabeo
    Norbert Farkas
    Brigitte Sloesen
    Abraham Palache
    Francis Shupo
    Sandrine I Samson
    BMC Public Health, 14
  • [2] Public health and economic benefits of new pediatric influenza vaccination programs in Argentina
    Giglio, Norberto
    Gentile, Angela
    Lees, Lydia
    Micone, Paula
    Armoni, Judith
    Reygrobellet, Camille
    Crepey, Pascal
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (03)
  • [3] Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives
    de Fougerolles, Thierry Rigoine
    Baissas, Theophile
    Perquier, Guillaume
    Vitoux, Olivier
    Crepey, Pascal
    Bartelt-Hofer, Jose
    Bricout, Helene
    Petitjean, Audrey
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [4] Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
    Uhart, Mathieu
    Bricout, Helene
    Clay, Emilie
    Largeron, Nathalie
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2259 - 2268
  • [5] Health and economic impact of the seasonal influenza vaccination programme in England
    Baguelin, Marc
    Jit, Mark
    Miller, Elizabeth
    Edmunds, William John
    VACCINE, 2012, 30 (23) : 3459 - 3462
  • [6] TRUST IN THE PUBLIC HEALTH SYSTEM AND SEASONAL-INFLUENZA VACCINATION
    Vasile, Marian
    Jderu, Gabriel
    Cristea, Darie
    TRANSYLVANIAN REVIEW OF ADMINISTRATIVE SCIENCES, 2024, (71E) : 113 - 129
  • [7] PUBLIC HEALTH AND ECONOMIC BENEFITS OF QUADRIVALENT INFLUENZA VACCINE IN COLOMBIA
    Jamotte, A.
    Caiccdo Navas, A. G.
    Macabeo, B.
    Lopez, J. G.
    Romero, M.
    Marrugo, R.
    Alfonso Quinones, P. A.
    VALUE IN HEALTH, 2015, 18 (07) : A590 - A590
  • [8] PUBLIC HEALTH AND ECONOMIC BENEFITS OF QUADRIVALENT INFLUENZA VACCINE IN MEXICO
    Guerrero, M. L.
    Jamotte, A.
    Tamayo, R.
    Hernandez, A.
    Galindo-Fraga, A.
    Ortiz, A. A.
    Cervantes, P.
    Lopez, J. G.
    Beigel, J. H.
    Ruiz-Palacios, G. M.
    VALUE IN HEALTH, 2017, 20 (09) : A784 - A784
  • [9] PUBLIC HEALTH AND ECONOMIC BENEFITS OF QUADRIVALENT INFLUENZA VACCINE IN PANAMA
    Jamotte, A.
    Caicedo Navas, A. G.
    Macabeo, B.
    Lopez, J. G.
    Moreno, B.
    Franco, D.
    Garcia, L. N.
    Isaza de Molto, Y.
    VALUE IN HEALTH, 2015, 18 (07) : A589 - A590
  • [10] An economic analysis of annual influenza vaccination of children
    Meltzer, MI
    Neuzil, KA
    Griffin, MR
    Fukuda, K
    VACCINE, 2005, 23 (08) : 1004 - 1014